AAMRNet is Australia’s leading multistakeholder expert group committed to combating the urgent global threat of antimicrobial resistance (AMR). AAMRNet is a public-private partnership, established and operated by MTPConnect, Australia’s life sciences innovation accelerator, delivering on a key recommendation of the report, Fighting Superbugs: A Report on the Inaugural Meeting of Australia’s Antimicrobial Resistance Stakeholders. AAMRNet leverages MTPConnect’s networks, resources and its reputation as an independent and trusted voice for the sector, and brings together experts from industry, clinicians, and research. AAMRNet is supported by industry contributions from: Pfizer ANZ, CSIRO, MSD Australia, GSK Australia, Recce Pharmaceuticals, Botanix Pharmaceuticals, SpeeDx, Medicines Australia, Tenmile, Biointelect, Monash Centre to Impact AMR and Bugworks Australia. AAMRNet is working with key national and international stakeholders across the biotechnology and pharmaceutical industry, the health and medical sector, clinicians, and government, to identify and tackle the challenges of AMR. AAMRNet provides a unified voice to support and promote Australia’s role in the global fight against the growing threat of drugs resistant infections. As the only body in Australia able to provide whole-of-sector representation, AAMRNet is uniquely placed to promote Australia’s role in the fight against AMR.
External link for Australian Antimicrobial Resistance Network (AAMRNet)
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
With our 2025 Antibacterial Therapeutics funding round now open for expressions of interest, learn more in this blog about our application process and how we come to funding decisions: https://lnkd.in/eeJ2aKr3 Medicines Discovery Catapult | LifeArc | Innovate UK | Vocal #AMR
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
A recent publication in Nature Portfolio Communications Medicine, co-authored by Erin Duffy, PhD, proposes a comprehensive One Health stewardship framework to address antimicrobial resistance (AMR). The authors emphasize that AMR is a complex, interconnected issue that requires stewardship throughout the entire antimicrobial lifecycle. The framework centers on four stewardship pillars: prevention, innovation, access, and care. Within the framework’s innovation pillar, CARB-X and Global Antibiotic R&D Partnership (GARDP) are recognized as important push incentives supporting antibiotic research and development. 🔗 Read the publication here: bit.ly/3KSyMvh #OneHealth #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology
The World Health Organization's (WHO) latest Global Antibiotic Resistance Surveillance (GLASS) report paints a frightening picture of the rise in #antimicrobialresistance across the globe. The data, now gathered from over 100 countries, shows that overall in 2023, 1 in 6 infections were resistant to antibiotics. The highest resistance was seen in UTIs, where 1 in 3 infections were caused by antibiotic-resistant bacteria. Resistance was highest in South-East Asia, right on Australia's doorstep, where almost a third of infections are resistant. The report also shows that the highest priority pathogens are becoming even more dangerous, with over 40% of E. coli and more than 55% of K. pneumoniae now resistant to third-generation cephalosporins and rates in the African region are now even exceeding 70%. With AMR already the direct cause of more than 1.1 million deaths around the world each year and the recent WHO antibiotic pipeline reports showing further deterioration in an already sparse R&D pipeline, the GLASS report highlights the urgent need for a much stronger response to AMR. Australian Antimicrobial Resistance Network (AAMRNet) continues to advocate for the implementation of a combination of 'push' and 'pull' incentives to support equitable access and R&D into new antibiotics and to strengthen regional preparedness and resilience against AMR. Thank you to the WHO and collaborators for this important work! 👉 https://lnkd.in/gdmgga-e Valeria Gigante Richard Alm The interim Australian Centre for Disease Control Australian Government Department of Health, Disability and Ageing Jamie Snashall Dr Lucas de Toca PSM Max Phillis Stephanie Williams Christina Bareja Dr. Angela Mina Vargas MTPConnect AMR Action+Insights CARB-X Global Antibiotic R&D Partnership (GARDP) AMR Action Fund Indo-Pacific Centre for Health Security
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
The Poster Abstract Call for the AMR Conference 2026 is now officially OPEN! We invite scientists to showcase their work on cutting-edge AMR research. This is your chance to share your science, connect with peers, and shape the future of antimicrobial innovation. Topics include: - Basic understanding of bacterial infections - Novel antibacterial therapies - Antibiotic mechanism of action studies - Preclinical development & enabling technologies - Novel diagnostics - AI-driven approaches - Clinical trial design Why should you apply? - Free poster presentation (no fee!) - Presenting author gets a complimentary full conference ticket - First prize of up to €1,000 📅 Deadline: January 7, 2026 All details & submission ➡️ https://lnkd.in/ehhEVyTG We can’t wait to see your posters and celebrate the most exciting work in AMR!
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
🌍 Join us for the virtual launch of the #WHO Global antibiotic resistance surveillance report, 2025 during the World Health Summit in Berlin! 📢 Together with thought leaders in AMR, scientists and national policy makers we will discuss: 🔹 Key findings from the new WHO report 🔹 Country reflections 🔹 Implications for clinical practice, research and policy 🔹 The path forward for strengthening AMR surveillance 🎤 The session will be moderated by Professor Sabiha Essack and will feature guest speakers Dr Muna ABU SIN, Dr Yukiko Nakatani, Dr Silvia Bertagnolio, Dr Olga Tosas, Dr Robert Skov, Dr Jennifer Cohn, Dr sonia sia, Dr Mariangela Batista Galvao Simao and Professor Dame Sally Davies. 👉 Join us in the global conversation on AMR: 🔗 https://lnkd.in/dCSt5dn8 #AntimicrobialResistance #GLASS #WHO #AMRSurveillance #WorldHealthSummit #AMR
This content isn’t available here
Access this content and more in the LinkedIn app
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
🔬 𝐍𝐞𝐰 𝐮𝐩𝐝𝐚𝐭𝐞 𝐨𝐧 𝐀𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜𝐃𝐁! GARDP’s AntibioticDB, an open-access database with information on more than 3,000 antibacterial agents, has been enhanced with new functionality. 🧪 𝐖𝐡𝐚𝐭’𝐬 𝐧𝐞𝐰: Compound pages now feature 2D chemical structures and molecular weights, helping researchers quickly understand the properties and potential of antibacterial agents. As one of the most comprehensive global resources of its kind, AntibioticDB supports transparency and collaboration in antibiotic R&D which is critical for accelerating innovation in the fight against drug-resistant infections. 👉 Explore the new update here: https://lnkd.in/gJZFDRDu #AMR #AntibioticResearch #OpenScience #GARDP
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
🆕WHO releases new reports on new tests and treatments in development for bacterial infections The World Health Organization has released two important reports that map the global landscape of innovation in antibacterial R&D and diagnostics. 🔹 The 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐚𝐧𝐭𝐢𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 𝐚𝐠𝐞𝐧𝐭𝐬 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: 𝐨𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐚𝐧𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝟐𝟎𝟐𝟓 shows that the number of antibacterials in clinical development has dropped from 97 to 90 since 2023 — with just 15 qualifying as innovative. Only a small fraction target WHO’s “critical” pathogens, and fewer still are designed for children or available as oral formulations. 🔹 The 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐥𝐲 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐧𝐝 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐢𝐧 𝐯𝐢𝐭𝐫𝐨 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐟𝐨𝐫 𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 𝐩𝐫𝐢𝐨𝐫𝐢𝐭𝐲 𝐩𝐚𝐭𝐡𝐨𝐠𝐞𝐧𝐬 highlights persistent gaps in affordable, accurate and easy-to-use tests — especially where the need is greatest. Both reports conclude that the global pipeline for tackling drug-resistant infections remains fragile and underfunded. Strengthening the pipeline will require coordinated investment in drug discovery, equitable access and diagnostic innovation. GARDP welcomes such analysis which serves as a valuable compass for the AMR community. Since GARDP was established in 2018 as a not-for-profit, it has helped create a new model for antibiotics research and development that is driven by public health need — with the first pivotal phase 3 antibiotic trial for a WHO priority pathogen to be sponsored and led by a not-for-profit, advancing treatments for neonatal sepsis and drug-resistant STIs, and supporting data sharing and access partnerships worldwide. Notably, Teri Roberts, Senior Public Health Manager at GARDP, contributed to the WHO expert group for the diagnostics report, further reflecting GARDP’s technical engagement in shaping the global AMR response. Read the WHO reports ⤵️ 📘 https://lnkd.in/gZXVZt3H 📗 https://lnkd.in/eCCqwf_b #AMR #Antibiotics #GARDP
Australian Antimicrobial Resistance Network (AAMRNet) members. Check your inbox for the October update! It highlights recent developments around the world including the formation of the World Health Organization Civil Society Task Force on #AMR, a couple of exciting new grant opportunities and AAMRNet's continuing activities in advocating for a stronger response to #AMR. If you would like to learn more about AAMRNet, and/or receive these updates, please email [email protected] MTPConnect Andrew Bowskill Stuart Dignam The Hon. Jaala Pulford GAICD Australian Government Department of Health, Disability and Ageing AMR Action+Insights The interim Australian Centre for Disease Control
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
Advocating for a stronger response to the global health crisis of antimicrobial resistance (AMR)
In February 2026, Sydney will play host to AMR 2026. A joint initiative of CSIRO and Fleming Initiative, AMR 2026 brings together global leaders in #AMR for a three-day cross-sector interactive event that will explore practical One Health solutions to #antimicrobialresistance. Find out more about the summit at https://lnkd.in/gHHavb3J Spaces are limited, so make sure you register your interest in attending early at https://lnkd.in/gNK82gt9 MTPConnect Branwen Morgan PhD Stuart Dignam Australian Antimicrobial Resistance Network (AAMRNet) Australian Government Department of Health, Disability and Ageing
Australian Antimicrobial Resistance Network (AAMRNet) reposted this
Thank you to CARB-X product developers, funders, and external speakers who convened at Imperial College London on September 30 for the annual CARB-X PD Conference! We welcomed more than 130 participants who came together to share and explore innovations to address antibiotic resistance. Attendees heard from a variety of presenters, including clinicians, CARB-X portfolio graduates, and CARB-X R&D Leaders across the therapeutics, preventatives, and diagnostics pillars. CARB-X extends its deepest gratitude to everyone who came together in London to participate in these important discussions on innovation to protect lives from bacterial infections. We enjoyed the opportunity to connect with everyone in person! #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Forschung, Technologie und Raumfahrt Gates Foundation Government of Canada Novo Nordisk Foundation Ministero dell'economia e delle finanze Centre for Cellular and Molecular Platforms (C-CAMP) German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE) Photos by Kalory | Photo & Video |